Online Stockmarket Trading Update

Viralytics Limited (VLA) is pleased to announce the receipt of Chinese notice to grant a patent involving of the use of CAVATAK TM RNA as an anti-cancer agent in human melanoma. The scope of this application involves, the delivery of viral RNA extracted directly from CAVATAKTM or synthetically manufactured RNA, to human melanoma cells to initiate an oncolytic viral infection and cell death. Existing patents granted to Viralytics involve the use of live whole virus while this new application involves the use of only the viral RNA “genetic blueprints” extracted from within the CAVATAKTM particle. The viral RNA may be delivered alone or in combination with an appropriate lipid formulation. The treatment regime offers a potential alternate strategy in producing oncolytic infection in human melanoma cells compared to the delivery of purified CAVATAKTM particles, which is currently under Phase I clinical evaluation in patients with late stage melanoma, breast, prostate and head/neck cancer.

Viralytics (VLA) principal asset is the intellectual property relating to CAVATAKTM, an Oncolytic Virus technology. CAVATAKTM is the trade name for Viralytics proprietary formulation of the Coxsackievirus Type A21 (CVA21). CVA21 is a human virus that occurs naturally in the community. CVA21 has been associated with upper respiratory infection ( “cold” like symptoms) and is self limiting, requiring no specific treatment for those infected to completely recover. In order to infect a cell, CVA21 must first attach to the outside of a cell, using a specific receptor on the cell’s surface (like a key fitting a lock). CVA21 uses two receptors to infect cells, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF). Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including: melanoma, prostate cancer, breast cancer, multiple myeloma and others.

www.viralytics.com

http://www.traderdealer.com.au/Fundamentals/vla

Viralytics Limited (VLA) is pleased to announce that it has been granted an Australian patent covering the use of Echoviruses for the treatment of all cancers bearing expression of the integrin α2β1. This patent also covers the right to use EVATAKTM (The trademarked name of Viralytics’ proprietary formulation of the Echovirus Type 1) in conjunction with other oncolytic viruses such as the Company’s lead product CAVATAKTM. The Company has received granted patents for this family of viruses from the USA, India, South Africa and Singapore.

Professor Darren Shafren (Chief Scientist Officer and inventor of the technology) said, “Numerous cancers, in particular OVARIAN AND GASTRIC CANCERS, have elevated surface levels of integrin α2β1. The presence of integrin α2β1 allows our family of echoviruses to lock onto the surface of cancer cells, leading to rapid infection and cellular destruction.” This is a similar process to the company’s lead candidate CAVATAKTM which uses an ICAM-1 receptor instead of the integrin α2β1 to lock onto the surface of cancer cells”.

Viralytics is listed on the Australian Securities Exchange (VLA). Its principal asset is the intellectual property relating to CAVATAKTM, an Oncolytic Virus technology. CAVATAKTM is the trade name for Viralytics’ proprietary formulation of the Coxsackievirus Type A21 (CVA21). CVA21 is a virus that occurs naturally in the community. CVA21 attaches to the outside of a cell, using a specific ‘receptor’ on the cell’s surface (like a key fitting a lock). CVA21 uses two receptors to infect cells, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF). Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including: melanoma, prostate cancer, breast cancer, multiple myeloma and others.

www.viralytics.com